Park Square has placed David Moller, MD, as Chief Scientific Officer at Poxel SA.
| less than a minute read
Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
Get in touch
Get in touch
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO).
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-23-14-44-49-507-6ab3e5e1470f335536fcf89c.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-22-15-19-50-498-6ab29c96af556e9074387689.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-15-18-23-35-620-6aa98d270810fd5205abd644.png)